<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46968">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986127</url>
  </required_header>
  <id_info>
    <org_study_id>CSAI</org_study_id>
    <secondary_id>2012-001723-12</secondary_id>
    <nct_id>NCT01986127</nct_id>
  </id_info>
  <brief_title>Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We study if the administration of intralesional Adalimumab (directly  injected in the
      stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared
      with placebo in patients with  Crohn's disease who had confirmed intestinal stenosis (3
      stenosis as maximum)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Success of endoscopic dilatation</measure>
    <time_frame>at week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful dilatation means the passage of the endoscope (or enteroscopy colonoscope) through the stenosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stenosis measure</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The endoscopic stenosis diameter will be estimated pre and post-dilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success of endoscopic dilatation</measure>
    <time_frame>at week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The success of endoscopic dilatation at week 52 means absence of clinical subocclusion, no necessity of surgical nor endoscopic dilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing</measure>
    <time_frame>at week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anastomotic strictures: We define mucosal healing as a Rutgeerts &lt; or equal 2 with at least 1 point of improvement (añadir el score)
Primary strictures: Absence of ulcers after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological cure</measure>
    <time_frame>at week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>We consider histological cure if:
Epithelial damage is &lt; or equal 1
Architectural changes is &lt; or equal 1
Infiltration of mononuclear cells in lamina propria is &lt; or equal 1
Polymorphonuclear cells in the lamina propria = 0
Polymorphonuclear cells in epithelium = 0
Absence of erosions and ulcers (based ib scoring system for Histologic Abnormalities in Crohn's disease Mucosal Biopsy Specimens - Title: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum Author(s): D'Haens, Geert R.; Geboes, Karel; Peeters, Mark; et al. Source: Gastroenterology  Volume: 114   Issue: 2   Pages: 262-267   Published: Feb., 1998)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients that develop anti-adalimumab antibodies</measure>
    <time_frame>at the end of the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>at the end of the study</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration of Adalimumab 80mg diluted in 5ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 ml of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>single intralesional administration during endoscopy process</description>
    <arm_group_label>Adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single intralesional administration during endoscopy</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes older than 18 years

          -  Patient diagnosed of CROHN´s disease

          -  Patient with intestinal stenosis length equal or less than 5cm previously confirmed
             with bowel magnetic resonance imaging (3 stenosis as maximum)

          -  Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with
             conventional colonoscopy and 10mm in case of accessible stenosis with balloon
             enteroscopy)

          -  Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)

          -  Patient capable of participate in the examinations required by the study

          -  Patient after being informed, give his/her informed consent in writing

        Exclusion Criteria:

          -  Patients with large intestinal stenosis (more than 6cm) and multiples

          -  Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF)
             drugs

          -  Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or
             HIV

          -  Patients with positive screening to Tuberculosis(positive PPD)

          -  Established contraindication to anti-TNF drugs

          -  Existence of fistulous tracts associated with intestinal stenosis

          -  Neoplastic process associated with stenosis or in another location

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Begoña González Suarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucía Márquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Mata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Moisés Broggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Huertas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Josep Trueta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lidia Argüello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enric Brullet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia González, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Echarri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complexo Hospitalario Arquitecto Marcide-Novoa Santos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Begoña Gonzalez Suarez, MD</last_name>
    <email>BGONZALS@CLINIC.UB.ES</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Varea Latorre, BSc</last_name>
    <email>svarea@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complexo Hospitalario Arquitecto Marcide -Novoa Santos</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Echarri, MD</last_name>
      <email>ana.echarri.piudo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Ana Echarri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enric Brullet, MD</last_name>
      <email>ebrullet@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Enric Brullet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Moises Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Mata, MD</last_name>
      <email>alfredo.matabilbao@sanitatintegral.org</email>
    </contact>
    <investigator>
      <last_name>Alfredo Mata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Marquez, MD</last_name>
      <email>lmarquez@hospitaldelmar.cat</email>
    </contact>
    <investigator>
      <last_name>Lucia Marquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Gonzalez Suarez, MD</last_name>
      <email>BGONZALS@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Begoña Gonzalez Suarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Huertas, MD</last_name>
      <email>chuertas.girona.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Carlos Huertas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital G.U. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecilia González, MD</last_name>
      <email>cgasanza@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Cecilia Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lidia Argüello, MD</last_name>
      <email>arguello_lid@gva.es</email>
    </contact>
    <investigator>
      <last_name>Lidia Argüello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Clínic per la Recerca Biomèdica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <keyword>Crohn disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
